IMTX
Immatics N.V.
Price Chart
Latest Quote
$10.17
+0.15 (+1.50%)
Current Price
| Previous Close | $10.02 |
| Open | $10.02 |
| Day High | $10.27 |
| Day Low | $10.01 |
| Volume | 89,978 |
Stock Information
Note: Financial values converted from EUR to USD
| Shares Outstanding | 136.67M |
| Total Debt | $17.16M |
| Cash Equivalents | $516.18M |
| Revenue | $42.44M |
| Net Income | $-244.00M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.39B |
| EPS (TTM) | $-1.95 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $930.98M |
| Sales | $42.44M |
| Income | $-244.00M |
| Book/sh | $3.81 |
| Cash/sh | $3.32 |
| Employees | 678 |
Financial Ratios
| Quick Ratio | 8.30 |
| Current Ratio | 8.78 |
| Debt/Eq | 3.31 |
Returns & Margins
| ROA | -22.44% |
| ROE | -43.21% |
| Operating Margin | -867.89% |
Ownership
| Insider Ownership | 17.58% |
| Institutional Ownership | 79.68% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -5.37 |
| P/S | 37.27 |
| P/B | 2.67 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $18.77 |
Technical Indicators
| SMA20 | $9.89 |
| SMA50 | $10.65 |
| SMA200 | $9.89 |
| RSI | 49.85 |
| ATR | 0.4807 |
| Shares Float | 69.59M |
| Short Float | 5.09% |
| Short Ratio | 8.78 |
| Volatility | 1.30 |
| Rel Volume | 0.18 |
Performance History
| Week | +6.83% |
| Month | -9.12% |
| Quarter | +4.41% |
| 6 Months | -1.74% |
| YTD | -2.68% |
| Year | +86.95% |
| 3 Years | -19.86% |
| 5 Years | -15.60% |
| 10 Years | +5.94% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $10.17 | 89,978 |
| 2026-06-24 | $10.02 | 675,900 |
| 2026-06-23 | $9.91 | 347,300 |
| 2026-06-22 | $9.78 | 553,600 |
| 2026-06-18 | $9.78 | 438,400 |
| 2026-06-17 | $9.52 | 293,000 |
| 2026-06-16 | $9.09 | 208,600 |
| 2026-06-15 | $9.43 | 163,400 |
| 2026-06-12 | $9.38 | 376,700 |
| 2026-06-11 | $9.06 | 236,600 |
| 2026-06-10 | $8.87 | 360,800 |
| 2026-06-09 | $9.16 | 596,100 |
| 2026-06-08 | $9.22 | 339,700 |
| 2026-06-05 | $9.79 | 1,129,300 |
| 2026-06-04 | $10.18 | 456,100 |
| 2026-06-03 | $10.20 | 547,200 |
| 2026-06-02 | $10.04 | 2,123,300 |
| 2026-06-01 | $11.14 | 636,500 |
| 2026-05-29 | $11.51 | 430,300 |
| 2026-05-28 | $11.45 | 142,300 |
| 2026-05-27 | $11.39 | 504,500 |
| 2026-05-26 | $11.19 | 670,000 |
About Immatics N.V.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in TÃŧbingen, Germany.
đ° Latest News
Analysts Are Updating Their Immatics N.V. (NASDAQ:IMTX) Estimates After Its First-Quarter Results
Simply Wall St. âĸ 2026-05-15T10:59:38Z
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-12T12:25:02Z
ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth
Zacks âĸ 2026-05-07T15:42:00Z
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
Zacks âĸ 2026-05-07T15:35:00Z
RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/Y
Zacks âĸ 2026-05-07T15:30:00Z
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-07T15:15:08Z
All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy
Zacks âĸ 2026-05-06T16:00:06Z
Twist Bioscience (TWST) Reports Q2 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-04T12:25:02Z
Immatics Phase 3 Progress Sharpens View On Anzu Cel Launch Upside
Simply Wall St. âĸ 2026-03-15T20:06:37Z
Immatics N.V. (IMTX) Seeing Strong Enrollment in a Key Phase 3 Trial of Drug Candidate
Insider Monkey âĸ 2026-03-13T18:31:53Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $55,161,146 | $178,097,152 | $61,710,860 | $197,521,153 |
| Operating Revenue | $55,161,146 | $178,097,152 | $61,710,860 | $197,521,153 |
| Expenses | ||||
| Interest Expense | $1,081,143 | $1,012,571 | $949,714 | $1,186,286 |
| Total Expenses | $263,179,442 | $222,228,583 | $177,968,009 | $163,288,008 |
| Other Income Expense | $-37,317,716 | $40,966,859 | $-9,466,286 | $12,164,572 |
| Net Non Operating Interest Income Expense | $18,552,001 | $27,560,001 | $14,873,144 | $1,643,429 |
| Interest Expense Non Operating | $1,081,143 | $1,012,571 | $949,714 | $1,186,286 |
| Operating Expense | $263,179,442 | $222,228,583 | $177,968,009 | $163,288,008 |
| Other Operating Expenses | $-5,410,286 | $-89,143 | $-1,301,714 | $-29,714 |
| General And Administrative Expense | $58,496,003 | $53,084,574 | $43,654,859 | $41,284,573 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-224,510,868 | $17,392,001 | $-108,170,291 | $31,660,573 |
| Net Interest Income | $18,552,001 | $27,560,001 | $14,873,144 | $1,643,429 |
| Interest Income | $19,633,144 | $28,572,573 | $15,822,858 | $2,829,714 |
| Normalized Income | $-187,567,202 | $-11,814,111 | $-98,932,869 | $23,643,751 |
| Net Income From Continuing And Discontinued Operation | $-224,510,868 | $17,392,001 | $-108,170,291 | $31,660,573 |
| Total Operating Income As Reported | $-208,018,296 | $-44,131,431 | $-116,257,149 | $34,233,145 |
| Net Income Common Stockholders | $-224,510,868 | $17,392,001 | $-108,170,291 | $31,660,573 |
| Net Income | $-224,510,868 | $17,392,001 | $-108,170,291 | $31,660,573 |
| Net Income Including Noncontrolling Interests | $-224,510,868 | $17,392,001 | $-108,170,291 | $31,660,573 |
| Net Income Continuous Operations | $-224,510,868 | $17,392,001 | $-108,170,291 | $31,660,573 |
| Pretax Income | $-226,784,011 | $24,395,430 | $-110,850,291 | $48,041,145 |
| Interest Income Non Operating | $19,633,144 | $28,572,573 | $15,822,858 | $2,829,714 |
| Operating Income | $-208,018,296 | $-44,131,431 | $-116,257,149 | $34,233,145 |
| Special Income Charges | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-1.84 | $0.16 | $-1.35 | $0.63 |
| Basic EPS | $-1.84 | $0.16 | $-1.35 | $0.64 |
| Other | ||||
| Tax Effect Of Unusual Items | $-374,050 | $11,760,747 | $-228,864 | $4,147,750 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-174,213,723 | $-1,587,429 | $-92,166,862 | $45,025,145 |
| Total Unusual Items | $-37,317,716 | $40,966,859 | $-9,466,286 | $12,164,572 |
| Total Unusual Items Excluding Goodwill | $-37,317,716 | $40,966,859 | $-9,466,286 | $12,164,572 |
| Reconciled Depreciation | $14,171,429 | $13,971,429 | $8,267,429 | $7,962,286 |
| EBITDA (Bullshit earnings) | $-211,531,439 | $39,379,431 | $-101,633,148 | $57,189,717 |
| EBIT | $-225,702,868 | $25,408,001 | $-109,900,577 | $49,227,431 |
| Diluted Average Shares | $139,826,789 | $122,051,549 | $92,053,355 | $77,951,173 |
| Basic Average Shares | $139,826,789 | $120,851,353 | $92,053,355 | $76,559,188 |
| Diluted NI Availto Com Stockholders | $-224,510,868 | $17,392,001 | $-108,170,291 | $31,660,573 |
| Tax Provision | $-2,273,143 | $7,003,429 | $-2,680,000 | $16,380,572 |
| Gain On Sale Of Security | $-37,317,716 | $40,966,859 | $-9,466,286 | $12,164,572 |
| Research And Development | $210,093,725 | $169,233,151 | $135,614,864 | $122,033,149 |
| Selling General And Administration | $58,496,003 | $53,084,574 | $43,654,859 | $41,284,573 |
| Other Gand A | $28,454,859 | $26,244,573 | $43,654,859 | $41,284,573 |
| Salaries And Wages | $30,041,144 | $26,840,001 | $24,891,430 | $23,912,001 |
| Minority Interests | - | - | - | $0 |
| Restructuring And Mergern Acquisition | - | - | - | $0 |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $551,448,028 | $655,100,604 | $246,965,727 | $230,538,297 |
| Total Assets | $642,670,889 | $795,595,468 | $582,817,172 | $466,080,023 |
| Total Non Current Assets | $66,661,718 | $76,104,004 | $69,251,432 | $35,046,859 |
| Other Non Current Assets | $878,857 | $1,048,000 | $689,143 | $2,908,572 |
| Non Current Prepaid Assets | $1,235,429 | $380,571 | $1,616,000 | $2,178,286 |
| Goodwill And Other Intangible Assets | $1,808,000 | $1,861,714 | $1,740,572 | $1,865,143 |
| Other Intangible Assets | $1,808,000 | $1,861,714 | $1,740,572 | $1,865,143 |
| Current Assets | $576,009,172 | $719,491,465 | $513,565,740 | $431,033,164 |
| Other Current Assets | $16,994,287 | $7,211,429 | $8,136,000 | $15,814,858 |
| Prepaid Assets | $14,765,715 | $13,769,144 | $12,136,001 | $11,942,858 |
| Receivables | $7,864,000 | $7,708,572 | $6,556,572 | $1,269,714 |
| Taxes Receivable | $893,714 | $1,014,857 | $1,878,857 | $1,178,286 |
| Accounts Receivable | $6,970,286 | $6,693,715 | $4,677,715 | $1,269,714 |
| Cash Cash Equivalents And Short Term Investments | $536,385,170 | $690,802,320 | $486,737,167 | $413,948,592 |
| Cash And Cash Equivalents | $395,334,877 | $270,569,156 | $249,682,298 | $169,736,008 |
| Hedging Assets Current | - | - | - | - |
| Other Receivables | - | - | - | - |
| Debt | ||||
| Total Debt | $17,868,572 | $18,517,715 | $17,602,287 | $16,642,287 |
| Long Term Debt And Capital Lease Obligation | $14,717,715 | $15,259,429 | $14,626,286 | $14,174,858 |
| Current Debt And Capital Lease Obligation | $3,150,857 | $3,258,286 | $2,976,000 | $2,467,429 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $89,414,862 | $138,633,150 | $334,110,874 | $233,676,583 |
| Total Non Current Liabilities Net Minority Interest | $40,258,288 | $60,933,717 | $155,194,293 | $112,017,148 |
| Non Current Deferred Liabilities | $25,540,573 | $45,674,288 | $140,563,436 | $97,794,291 |
| Non Current Deferred Taxes Liabilities | $4,350,857 | $6,633,143 | $8,532,572 | $11,212,572 |
| Current Liabilities | $49,156,574 | $77,699,432 | $178,916,580 | $121,659,435 |
| Other Current Liabilities | $1,771,429 | $3,642,286 | $21,949,715 | $30,034,287 |
| Current Deferred Liabilities | $18,075,429 | $41,037,716 | $114,744,006 | $74,236,575 |
| Payables And Accrued Expenses | $24,208,001 | $27,956,573 | $37,787,430 | $14,921,144 |
| Payables | $3,074,286 | $15,864,001 | $17,741,715 | $14,921,144 |
| Total Tax Payable | $2,685,714 | $4,307,429 | $8,980,572 | $8,827,429 |
| Income Tax Payable | $36,571 | $2,012,572 | $4,912,000 | $4,912,000 |
| Accounts Payable | $388,571 | $11,556,572 | $8,761,143 | $14,921,144 |
| Other Non Current Liabilities | - | - | $4,571 | $48,000 |
| Equity | ||||
| Common Stock Equity | $553,256,028 | $656,962,319 | $248,706,298 | $232,403,440 |
| Total Equity Gross Minority Interest | $553,256,028 | $656,962,319 | $248,706,298 | $232,403,440 |
| Stockholders Equity | $553,256,028 | $656,962,319 | $248,706,298 | $232,403,440 |
| Gains Losses Not Affecting Retained Earnings | $-9,819,429 | $1,178,286 | $-1,869,714 | $-1,692,572 |
| Other Equity Adjustments | $-9,819,429 | $1,178,286 | $-1,869,714 | $-1,692,572 |
| Retained Earnings | $-898,272,045 | $-673,761,177 | $-691,153,177 | $-582,982,886 |
| Other | ||||
| Ordinary Shares Number | $153,224,501 | $138,914,486 | $96,751,764 | $87,623,660 |
| Share Issued | $153,224,501 | $138,914,486 | $96,751,764 | $87,623,660 |
| Tangible Book Value | $551,448,028 | $655,100,604 | $246,965,727 | $230,538,297 |
| Invested Capital | $553,256,028 | $656,962,319 | $248,706,298 | $232,403,440 |
| Working Capital | $526,852,598 | $641,792,032 | $334,649,160 | $309,373,730 |
| Capital Lease Obligations | $17,868,572 | $18,517,715 | $17,602,287 | $16,642,287 |
| Total Capitalization | $553,256,028 | $656,962,319 | $248,706,298 | $232,403,440 |
| Additional Paid In Capital | $1,459,814,930 | $1,328,155,495 | $940,761,190 | $816,202,327 |
| Capital Stock | $1,532,572 | $1,389,714 | $968,000 | $876,571 |
| Common Stock | $1,532,572 | $1,389,714 | $968,000 | $876,571 |
| Non Current Deferred Revenue | $21,189,715 | $39,041,145 | $132,030,864 | $86,581,719 |
| Long Term Capital Lease Obligation | $14,717,715 | $15,259,429 | $14,626,286 | $14,174,858 |
| Current Deferred Revenue | $18,075,429 | $41,037,716 | $114,744,006 | $74,236,575 |
| Current Capital Lease Obligation | $3,150,857 | $3,258,286 | $2,976,000 | $2,467,429 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,950,857 | $1,804,572 | $1,459,429 | $921,143 |
| Current Accrued Expenses | $21,133,715 | $12,092,572 | $20,045,715 | $11,098,286 |
| Net PPE | $62,739,432 | $72,813,718 | $65,205,718 | $30,273,144 |
| Accumulated Depreciation | $-34,014,859 | $-36,643,430 | $-26,131,430 | $-23,408,001 |
| Gross PPE | $96,754,291 | $109,457,148 | $91,337,147 | $53,681,146 |
| Leases | $32,873,145 | $35,905,145 | $29,043,430 | $4,384,000 |
| Other Properties | $39,325,716 | $43,974,859 | $34,981,716 | $40,532,573 |
| Machinery Furniture Equipment | $10,169,143 | $14,544,001 | $12,627,429 | $8,764,572 |
| Buildings And Improvements | $14,386,286 | $15,033,144 | $14,684,572 | $14,181,715 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $141,050,293 | $420,233,164 | $237,054,869 | $244,212,584 |
| Current Provisions | - | - | - | - |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-209,635,439 | $-199,440,010 | $-14,547,429 | $107,332,577 |
| Operating Activities | ||||
| Operating Cash Flow | $-201,858,296 | $-180,605,723 | $20,832,001 | $114,435,434 |
| Cash Flow From Continuing Operating Activities | $-201,858,296 | $-180,605,723 | $20,832,001 | $114,435,434 |
| Operating Gains Losses | $37,888,002 | $-41,107,431 | $10,045,715 | $-9,133,715 |
| Investing Activities | ||||
| Capital Expenditure | $-7,777,143 | $-18,834,287 | $-35,379,430 | $-7,102,857 |
| Investing Cash Flow | $234,042,297 | $-174,156,580 | $-35,872,002 | $-239,761,155 |
| Cash Flow From Continuing Investing Activities | $234,042,297 | $-174,156,580 | $-35,872,002 | $-239,761,155 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $122,640,006 | $392,011,448 | $103,318,862 | $153,696,008 |
| Financing Cash Flow | $111,260,577 | $365,353,161 | $96,589,719 | $141,382,864 |
| Cash Flow From Continuing Financing Activities | $111,260,577 | $365,353,161 | $96,589,719 | $141,382,864 |
| Net Other Financing Charges | $-7,997,715 | $-24,358,858 | $-2,330,286 | $-9,064,000 |
| Net Common Stock Issuance | $122,640,006 | $392,011,448 | $103,318,862 | $153,696,008 |
| Common Stock Issuance | $122,640,006 | $392,011,448 | $103,318,862 | $153,696,008 |
| Other | ||||
| Repayment Of Debt | $-3,381,714 | $-2,299,429 | $-4,398,857 | $-3,249,143 |
| End Cash Position | $395,334,877 | $270,569,156 | $249,682,298 | $169,736,008 |
| Beginning Cash Position | $270,569,156 | $249,682,298 | $169,736,008 | $151,993,150 |
| Effect Of Exchange Rate Changes | $-18,678,858 | $10,296,001 | $-1,603,429 | $1,685,714 |
| Changes In Cash | $143,444,579 | $10,590,858 | $81,549,718 | $16,057,144 |
| Net Issuance Payments Of Debt | $-3,381,714 | $-2,299,429 | $-4,398,857 | $-3,249,143 |
| Net Long Term Debt Issuance | $-3,381,714 | $-2,299,429 | $-4,398,857 | $-3,249,143 |
| Long Term Debt Payments | $-3,381,714 | $-2,299,429 | $-4,398,857 | $-3,249,143 |
| Net Investment Purchase And Sale | $241,819,441 | $-155,324,579 | $-664,000 | $-232,717,726 |
| Sale Of Investment | $628,410,317 | $359,360,018 | $473,993,167 | $14,508,572 |
| Purchase Of Investment | $-386,590,876 | $-514,684,597 | $-474,657,167 | $-247,226,298 |
| Net Intangibles Purchase And Sale | $-282,286 | $-237,714 | $-180,571 | $-545,143 |
| Purchase Of Intangibles | $-282,286 | $-237,714 | $-180,571 | $-545,143 |
| Net PPE Purchase And Sale | $-7,494,858 | $-18,594,287 | $-35,027,430 | $-6,498,286 |
| Sale Of PPE | $0 | $2,286 | $171,429 | $59,429 |
| Purchase Of PPE | $-7,494,858 | $-18,596,572 | $-35,198,859 | $-6,557,715 |
| Taxes Refund Paid | $-5,062,857 | $-14,969,144 | $-3,382,857 | $-256,000 |
| Interest Received Cfo | $30,648,002 | $17,834,287 | $11,619,429 | $1,884,572 |
| Interest Paid Cfo | $-1,081,143 | $-1,012,571 | $-331,429 | $-794,286 |
| Change In Working Capital | $-50,245,717 | $-172,320,009 | $96,674,291 | $42,580,574 |
| Change In Other Working Capital | $-42,988,574 | $-171,134,866 | $98,284,576 | $52,067,431 |
| Change In Other Current Assets | $-6,980,572 | $830,857 | $1,797,714 | $-8,996,572 |
| Change In Receivables | $-276,571 | $-2,016,000 | $-3,408,000 | $-490,286 |
| Changes In Account Receivables | $-276,571 | $-2,016,000 | $-3,408,000 | $-490,286 |
| Other Non Cash Items | $-18,552,001 | $-27,560,001 | $-14,873,144 | $-1,643,429 |
| Stock Based Compensation | $17,160,001 | $20,162,287 | $23,662,858 | $25,794,287 |
| Deferred Tax | $-2,273,143 | $7,003,429 | $-2,680,000 | $16,380,572 |
| Deferred Income Tax | $-2,273,143 | $7,003,429 | $-2,680,000 | $16,380,572 |
| Depreciation Amortization Depletion | $14,171,429 | $13,971,429 | $8,267,429 | $7,962,286 |
| Depreciation And Amortization | $14,171,429 | $13,971,429 | $8,267,429 | $7,962,286 |
| Gain Loss On Investment Securities | $-1,977,143 | $-19,730,287 | $2,376,000 | $-12,508,572 |
| Net Foreign Currency Exchange Gain Loss | $39,008,002 | $-21,378,287 | $7,841,143 | $3,374,857 |
| Gain Loss On Sale Of PPE | $857,143 | $1,143 | $-171,429 | $0 |
| Net Income From Continuing Operations | $-224,510,868 | $17,392,001 | $-108,170,291 | $31,660,573 |
| Change In Payables And Accrued Expense | - | - | - | - |
| Change In Payable | - | - | - | - |
| Change In Account Payable | - | - | - | - |
Fetched: 2026-06-23